oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2018 ( 2 )

2017 ( 5 )

2016 ( 4 )

2015 ( 81 )

Custom range...

Search Results: 1 - 10 of 2233 matches for " Lyford Joanna "
All listed articles are free for downloading (OA Articles)
Page 1 /2233
Display every page Item
Selected highlights from the 50th Annual Scientific Session of the American College of Cardiology, Orlando, USA, 18-21 March 2001
Joanna Lyford
Trials , 2001, DOI: 10.1186/cvm-2-2-085
Abstract: Clopidogrel, in addition to standard medications, confers significant benefits to patients with acute coronary syndromes. Salim Yusuf (McMaster University, Hamilton, Canada) presented results from CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events) study for the first time. Compared with placebo, clopido-grel was shown to reduce, by 20%, the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS).Clopidogrel is an advanced antiplatelet agent that works by direct blockade of adenosine diphosphate receptors. It is currently indicated for the prevention of atherosclerotic events in patients with atherosclerotic disease, documented by recent myocardial infarction (MI) or ischemic stroke, or peripheral arterial disease. The CURE study involved 12,562 patients in 28 countries and ran from December 1998 to December 2000. "It provides important new findings that constitute a major step forward and could lead to a very significant improvement in the treatment of patients at risk of heart attack, stroke, and cardiovascular death", said Yusuf.In the study, subjects who were admitted to hospital with suspected ACS were given aspirin (75-325 mg/day) then randomised to receive either clopidogrel (75 mg/day) or placebo. Subjects also received an initial loading dose of clopidogrel 300 mg orally (or matching placebo) within 24 hours of symptom onset. Treatment was continued for three months to one year, and the primary endpoint was a composite of MI, stroke (any type), cardiovascular death (CVD), and refractory ischemia.Treatment with clopidogrel was found to confer a risk reduction of 20% on the composite endpoint, at a highly significant P = 0.00005. This benefit was incremental and independent of concomitant drug treatment and revascularization. Importantly, high and low risk patients showed a similar reduction in events. Also, the effects on the endpoints became apparent within two hours and continued
Different mechanisms by which CMV predisposes to CAD in men and women
Lyford Joanna
Current Controlled Trials in Cardiovascular Medicine , 2001,
Abstract:
Statins reduce dementia risk by 70%
Lyford Joanna
Current Controlled Trials in Cardiovascular Medicine , 2001,
Abstract:
'No independent link' between diabetes and poor outcomes after CABG/PTCA
Lyford Joanna
Current Controlled Trials in Cardiovascular Medicine , 2001,
Abstract:
Coronary event risk needs to be quantified before advising aspirin for primary prevention
Lyford Joanna,Sanmuganathan PS,Ghahramani P,Jackson PR
Current Controlled Trials in Cardiovascular Medicine , 2001, DOI: 10.1186/cvm-2001-72100
Abstract:
Dietary changes take two years to reduce heart attack risk
Lyford Joanna,Hooper L,Summerbell CD,Higgins JPT
Current Controlled Trials in Cardiovascular Medicine , 2001, DOI: 10.1186/cvm-2001-71954
Abstract:
Statins not effective in reducing osteoporotic fractures
Lyford Joanna,Reid IR,Hague W,Emberson J
Current Controlled Trials in Cardiovascular Medicine , 2001, DOI: 10.1186/cvm-2001-72053
Abstract:
Caerphilly study finds no link between homocysteine and CHD
Lyford Joanna,Fallon UB,Ben-Shlomo Y,Elwood P
Current Controlled Trials in Cardiovascular Medicine , 2001, DOI: 10.1186/cvm-2001-72106
Abstract:
Evidence for increased risk of venous thrombosis during air travel
Lyford Joanna,Bendz B,Rostrup M,Sevre K
Current Controlled Trials in Cardiovascular Medicine , 2000, DOI: 10.1186/cvm-2001-72061
Abstract:
Community-based study highlights sex differential in post-MI mortality
Lyford Joanna,Vaccarino V,Krumholz HM,Yarzebski J
Current Controlled Trials in Cardiovascular Medicine , 2001, DOI: 10.1186/cvm-2001-72056
Abstract:
Page 1 /2233
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.